Apollon Wealth Management LLC Sells 7,046 Shares of Icon Plc $ICLR

Key Points

• Apollon Wealth Management cut its Icon stake by 35.6%, selling 7,046 shares and retaining 12,773 shares valued at approximately $2.17 million. Institutional investors collectively own 95.61% of Icon.
• Icon’s latest quarterly results modestly beat estimates, with earnings of $2.66 per share and revenue of $2.02 billion, although revenue declined 0.9% year over year and earnings fell from $3.31 per share.
• ICLR shares opened at $214.16, near their 12-month high, while analysts maintained a consensus “Hold” rating and an average price target of $178.81. Insiders sold roughly $3.94 million of stock during the quarter.

Apollon Wealth Management LLC decreased its position in Icon Plc (NASDAQ:ICLR - Free Report) by 35.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,773 shares of the medical research company's stock after selling 7,046 shares during the quarter. Apollon Wealth Management LLC's holdings in Icon were worth $2,171,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Polianta Ltd acquired a new stake in shares of Icon during the 2nd quarter worth about $1,876,000. Maple Rock Capital Partners Inc. lifted its stake in Icon by 257.8% during the second quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company's stock worth $208,383,000 after purchasing an additional 864,300 shares during the last quarter. Royal Bank of Canada lifted its stake in Icon by 68.0% during the first quarter. Royal Bank of Canada now owns 153,728 shares of the medical research company's stock worth $17,011,000 after purchasing an additional 62,225 shares during the last quarter. Trinity Street Asset Management LLP boosted its holdings in Icon by 27.1% in the second quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company's stock valued at $266,725,000 after purchasing an additional 327,314 shares in the last quarter. Finally, VELA Investment Management LLC boosted its holdings in Icon by 511.4% in the second quarter. VELA Investment Management LLC now owns 12,192 shares of the medical research company's stock valued at $2,118,000 after purchasing an additional 10,198 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company's stock.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $214.16 on Thursday. The firm has a market capitalization of $16.40 billion, a price-to-earnings ratio of 50.27, a price-to-earnings-growth ratio of 11.98 and a beta of 1.24. Icon Plc has a 12 month low of $66.57 and a 12 month high of $214.94. The business's 50 day simple moving average is $170.36 and its 200-day simple moving average is $146.19. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95.

Icon (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.62 by $0.04. The company had revenue of $2.02 billion during the quarter, compared to analysts' expectations of $2.01 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%. The business's revenue for the quarter was down .9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.31 earnings per share. As a group, equities analysts forecast that Icon Plc will post 9.55 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ciaran Murray sold 2,677 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $439,804.33. Following the completion of the sale, the director directly owned 20,452 shares in the company, valued at approximately $3,360,059.08. This represents a 11.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John Climax sold 5,005 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $875,875.00. Following the completion of the sale, the director owned 2,087 shares of the company's stock, valued at approximately $365,225. This represents a 70.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 23,068 shares of company stock worth $3,936,744 in the last quarter. Insiders own 44.00% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on ICLR shares. Truist Financial reiterated a "buy" rating and issued a $209.00 price target (up from $207.00) on shares of Icon in a research note on Friday, July 31st. Citigroup reduced their price objective on shares of Icon from $180.00 to $175.00 and set a "neutral" rating for the company in a research report on Friday, September 18th. UBS Group started coverage on shares of Icon in a research report on Wednesday, September 30th. They set a "neutral" rating and a $195.00 price objective for the company. Weiss Ratings restated a "sell (d)" rating on shares of Icon in a report on Wednesday, August 26th. Finally, Evercore reaffirmed an "outperform" rating and issued a $240.00 target price on shares of Icon in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $178.81.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: ICON projected mid-single-digit revenue growth in 2027, supported by record net bookings of approximately $3.15 billion. The company also highlighted a backlog of about $24.5 billion, providing visibility into future revenue. ICON signals mid-single-digit revenue expansion in 2027
• Positive Sentiment: Third-quarter adjusted earnings of $2.66 per share and revenue of $2.02 billion exceeded consensus estimates of $2.64 and $2.01 billion, respectively. ICON also raised its 2026 guidance, reinforcing confidence in near-term execution. ICON Q3 earnings and revenues beat estimates
• Positive Sentiment: The company completed a $2.15 billion note issuance and redeemed 2.36 million shares during the quarter. The share redemption may support per-share results and signals continued capital-return activity, although the new debt increases leverage. ICON completes note issuance and share redemption
• Neutral Sentiment: Management’s earnings call emphasized demand across clinical research services and the company’s sizeable backlog, but investors will watch whether bookings convert into revenue growth as expected. ICON Q3 2026 earnings call transcript
• Negative Sentiment: Despite the earnings beat, quarterly revenue declined 0.9% year over year and earnings fell from $3.31 per share in the prior-year period. This indicates that the recovery remains dependent on stronger future growth. ICON Q3 non-GAAP earnings and revenue report
• Neutral Sentiment: Chief Accounting Officer Emer Lyons sold 272 shares to cover tax withholding tied to equity vesting. The relatively small, tax-related transaction is unlikely to materially affect investor sentiment. ICON insider share sale

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.